SARS-CoV-2 infections may be 10 times higher than reported cases, according to new data from a Centers for Disease Control and Prevention partnership with commercial laboratories to test de-identified clinical blood specimens for antibodies in Connecticut, South Florida, the New York City area, Missouri, Utah and western Washington state.

The seroprevalence survey includes people who had blood specimens tested for SARS-CoV-2 antibodies for reasons unrelated to COVID-19, such as for a routine or sick visit. CDC is working with state and local health departments to publish additional results from California, Louisiana, Minnesota, and Pennsylvania.

The survey aims to test about 1,800 samples from each of the 10 areas every 3 to 4 weeks to track changes in the percentage of people tested who have antibodies against SARS-CoV-2 in each area.

Related News Articles

Headline
The AHA’s American Organization of Nursing Leadership affiliate, the American Nurses Association, and Johnson & Johnson this week released a report…
Headline
Pfizer Inc. today announced that the federal government has agreed to purchase an additional 200 million doses of its COVID-19 vaccine. The deal raises the…
Headline
The Health Resources and Services Administration yesterday awarded rural health clinics about $49,500 each for outreach to increase COVID-19 vaccinations in…
Perspective
The widespread belief that we have completely turned the corner in our fight against COVID-19 does not apply equally to all parts of the country. In many…
Headline
Throughout the COVID-19 pandemic, Sutter Health in Northern California used the range of its system to meet the needs of patients, staff and clinicians, from…
Headline
U.S. life expectancy fell by an average of 1.5 years in 2020 to 77.3 years, primarily due to COVID-19, the Centers for Disease Control and Prevention reported…